Arbutus Biopharma





Please Login or Register

Login|Register FREE

Stock Price
Open: 5.05
Prev. Close: 5.25
Low/Hi: 5.03 - 5.24
52-Week: 2.95 - 8.25
Equity: 133,453
90-Day Avg: 198,624
Option: 32
90-Day Avg: 111
Todays Stock Vol: 71.9
20-Day (HV): 56.1
52-Week (HV): 67.6
30-Day IV: 65.0 +6.2
IV Pct Rank: 7% Subdued
Div. Yield:
Earnings: 3-May (Est.)
P/E Ratio:
Market Cap: 291.6 M
Short Int Pct: 0.0%
Pct Held By Inst.: 98.2%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ABUS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Primary Exchange: NASDAQ
NAICS Pharmaceutical Preparation Manufacturing

ABUS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 412.3 M 4.12318E+08 204 204 0.01% 0.000137925 125 K 124934
IBB iShares Nasdaq Biotechnology Index Fund 9.6 B 9.55195E+09 193 193 0.04% 0.0004 3.6 M 3589550
PRFZ PowerShares FTSE RAFI US 1500 Small-Mid Portfolio 2.4 B 2.35E+09 1,392 1392 0.03% 0.0003 696 K 696491
PZI PowerShares Zacks Micro Cap 20.5 M 2.05E+07 399 399 0.28% 0.00278 57 K 56920
UBIO Proshares UltraPro Nasdaq Biotechnology 39.9 M 3.98758E+07 198 198 0.01% 8.35543E-05 11 K 10910

Wait, Before You Leave...

Want to Know More About ABUS Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon